The GLP-1 Patent Cliff: When Biosimilars Could Actually Arrive
Semaglutide's patent protection expires at different times in different countries, which is already shaping early biosimilar competition in some markets.
By the GLP Semaglutide editorial team · Last updated March 18, 2026
Patent and regulatory exclusivity periods for semaglutide differ by country, which means biosimilar or generic competition is expected to arrive on a staggered, country-by-country basis rather than as a single global event.
Biosimilars face a longer road than small-molecule generics
Because semaglutide is a peptide, follow-on competitors are regulated as biosimilars in most major markets, requiring comparability studies rather than the simpler bioequivalence pathway used for small-molecule generic pills — a process that adds years even after patents clear.
Why timelines cited online vary so much
Specific expiration dates depend on patent filings, extensions, and legal challenges that are still unfolding in some jurisdictions. National patent office databases are the authoritative source, not secondary market analysis.
Primary sources